Loading stock…

Solventum Corporation (SOLV) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Solventum Corporation

SOLVMarket cap $15BPrice $85.9

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes medical devices, wound care products, and dental supplies used in hospitals worldwide. Spun off from 3M in 2024, it inherited decades of engineering muscle but now must prove it can stand on its own outside the conglomerate's shadow.

In Bastion Portfolios?

52W Return+19%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+1%3

Revenue Forecast

Rev CAGR (1y)-1%2

Rev CAGR (3y)+2%2

Rev CAGR (5y)+3%2

Earnings Forecast

EPS Growth Y+1-18%2

EPS Growth Y+2+2%4

EPS Growth Y+3+10%7

Quality

Margins

EBIT Margin8%4

Net Income Margin17%7

Free Cash Flow Margin-1%2

Debt

Net Debt/EBITDA3.92

Efficiency

ROE34%9

ROA10%8

Earnings Stability77

GEAR+WEAK27

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)137

P/E Ratio (Forward 3y)107

P/BV3.05

EV Multiples

EV/EBITDA Fwd106

EV/EBIT Fwd118

Yield

Free Cash Flow Yield-0.8%2

Dividend Yieldna–

Momentum

Short term

1 month return-5%5

3 month return+14%9

YTD return+8%6

Mid term

Price vs 52wHigh91%9

1 year return+19%7

Long term

3 year return+7%3

5 year return+7%4

Risk Shield

Price Risk

Beta0.86

Volatility29%7

Free Cash Flow

Free Cash Flow Margin-1%2

Free Cash Flow Yield-0.8%2

Quality

ROCE5%3

Earnings Stability77

Net Debt/EBITDA3.92

02Growth

Is it actually growing, and how fast?

SOLVSolventum

Revenue FY25$8.3B

GROWTH RATING↗

VERY WEAK9 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+1%3

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-18%2

EPS growth, FY27E+2%4

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 0.8%/yr over the last 3 years and is set to keep growing around 2%/yr.

Earnings are set to grow in step with sales (EPS about 2%/yr vs revenue 2%/yr). One year dips: EPS falls 18% next year.

WEAKNESSES

Growth is the weak spot here, trailing 91% of companies worldwide.

Revenue grew 0.8%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE65 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return+14%9

YTD return+8%6

MID & LONG-TERM▾SCORE

% of 52-week high91%9

1-year return+19%7

3-year return+7%3

5-year return+7%4

MOMENTUM ASSESSMENT

STRENGTHS

It's up 19% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+14%).

WATCH

Returns sit at the market level over the past month (-5%) and so far this year (+8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+7.3% over three years and +7.3% over five), behind 60% of the market.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Solventum Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

SOLVSolventum

Revenue FY25$8.3B

GROWTH RATING↗

VERY WEAK9 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+1%3

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-18%2

EPS growth, FY27E+2%4

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 0.8%/yr over the last 3 years and is set to keep growing around 2%/yr.

Earnings are set to grow in step with sales (EPS about 2%/yr vs revenue 2%/yr). One year dips: EPS falls 18% next year.

WEAKNESSES

Growth is the weak spot here, trailing 91% of companies worldwide.

Revenue grew 0.8%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE65 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return+14%9

YTD return+8%6

MID & LONG-TERM▾SCORE

% of 52-week high91%9

1-year return+19%7

3-year return+7%3

5-year return+7%4

MOMENTUM ASSESSMENT

STRENGTHS

It's up 19% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+14%).

WATCH

Returns sit at the market level over the past month (-5%) and so far this year (+8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+7.3% over three years and +7.3% over five), behind 60% of the market.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Solventum Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community